Pacira BioSciences senior vice president Lauren Riker sells $217,920 in stock

Pacira BioSciences senior vice president Lauren Riker sold 6,000 shares of the company's stock in early October 2026. The transaction, conducted under a pre-arranged trading plan, netted her $217,920. The shares were disposed of at $36.32 each, close to the stock's 52-week peak of $36.46. Over the past week, the stock price has risen by 44%, while its value has skyrocketed by 57% in the last year.

This move was made following the exercise of stock options, which Ms. Riker acquired through her employment, valued at $194,100. She now holds a total of 62,284.242 shares of Pacira BioSciences common stock. InvestingPro analysts view the stock as potentially undervalued, assigning it a Piotroski Score of 9, indicating robust financial health.

The company's revenue grew by 6% in the second quarter, reaching $192.4 million, slightly exceeding expectations. This growth follows the successful performance of the company's principal products and a significant coverage win with a payer. In a separate development, Viatris acquired Pacira Pharmaceuticals for $1.65 billion, leading to a downgrade of Pacira's stock from 'Buy' to 'Hold' by Jefferies, with a price target of $36.00.

Despite this, Oppenheimer maintains an 'Outperform' rating and a price target of $32.00, citing a positive outlook for Exparel as it enters a growth phase. These events shed light on the shifting market landscape surrounding Pacira BioSciences.